AstraZeneca Historical Financial Ratios
| AZN Stock | USD 75.17 0.14 0.19% |
AstraZeneca PLC is presently reporting on over 101 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0285, PTB Ratio of 9.53 or Days Sales Outstanding of 113 will help investors to properly organize and evaluate AstraZeneca PLC ADR financial condition quickly.
AstraZeneca |
About AstraZeneca Financial Ratios Analysis
AstraZeneca PLC ADRFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate AstraZeneca PLC investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on AstraZeneca financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across AstraZeneca PLC history.
AstraZeneca PLC Financial Ratios Chart
AstraZeneca PLC ADR financial ratios usually calculated using numerical values taken directly from AstraZeneca PLC financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about AstraZeneca PLC. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, AstraZeneca PLC's PB Ratio is very stable compared to the past year. As of the 28th of April 2024, Free Cash Flow Per Share is likely to grow to 2.21, while Price To Sales Ratio is likely to drop 2.62. Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing AstraZeneca PLC ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on AstraZeneca PLC sales, a figure that is much harder to manipulate than other AstraZeneca PLC ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is AstraZeneca PLC ADR dividend as a percentage of AstraZeneca PLC stock price. AstraZeneca PLC ADR dividend yield is a measure of AstraZeneca PLC stock productivity, which can be interpreted as interest rate earned on an AstraZeneca PLC investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from AstraZeneca PLC's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. At this time, AstraZeneca PLC's PB Ratio is very stable compared to the past year. As of the 28th of April 2024, Free Cash Flow Per Share is likely to grow to 2.21, while Price To Sales Ratio is likely to drop 2.62.
| 2021 | 2022 | 2023 | 2024 (projected) | Dividend Yield | 0.0232 | 0.0206 | 0.0213 | 0.0285 | Price To Sales Ratio | 4.44 | 4.77 | 4.59 | 2.62 |
AstraZeneca PLC fundamentals Correlations
Click cells to compare fundamentals
AstraZeneca PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AstraZeneca PLC fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 5.32 | 4.93 | 4.44 | 4.77 | 4.59 | 2.62 | |
| Dividend Yield | 0.0277 | 0.0272 | 0.0232 | 0.0206 | 0.0213 | 0.0285 | |
| Ptb Ratio | 9.88 | 8.4 | 4.23 | 5.71 | 5.38 | 9.53 | |
| Days Sales Outstanding | 77.55 | 77.49 | 104.94 | 81.66 | 107.98 | 113.37 | |
| Book Value Per Share | 5.04 | 5.95 | 13.76 | 11.87 | 12.53 | 13.16 | |
| Free Cash Flow Yield | 0.003923 | 0.0167 | 0.0226 | 0.0342 | 0.0312 | 0.029 | |
| Invested Capital | 1.39 | 1.3 | 0.78 | 0.79 | 0.73 | 0.69 | |
| Operating Cash Flow Per Share | 1.14 | 1.83 | 2.09 | 3.14 | 3.31 | 3.48 | |
| Capex To Depreciation | (0.65) | (0.83) | (0.34) | (0.47) | (0.77) | (0.8) | |
| Pb Ratio | 9.88 | 8.4 | 4.23 | 5.71 | 5.38 | 9.53 | |
| Ev To Sales | 5.85 | 5.4 | 5.1 | 5.29 | 5.09 | 2.78 | |
| Free Cash Flow Per Share | 0.2 | 0.84 | 1.32 | 2.32 | 2.1 | 2.21 | |
| Inventory Turnover | 1.54 | 1.32 | 1.38 | 2.64 | 1.52 | 2.54 | |
| Net Income Per Share | 0.51 | 1.22 | 0.0392 | 1.05 | 1.91 | 2.0 | |
| Days Of Inventory On Hand | 236.83 | 277.18 | 263.63 | 138.42 | 239.45 | 141.81 | |
| Payables Turnover | 0.35 | 0.34 | 0.66 | 0.65 | 2.53 | 2.66 | |
| Cash Per Share | 2.24 | 2.39 | 3.04 | 2.05 | 1.88 | 1.57 | |
| Pocfratio | 43.7 | 27.35 | 27.88 | 21.57 | 20.34 | 26.85 | |
| Interest Coverage | 2.04 | 3.95 | 0.81 | 2.79 | 5.16 | 4.9 | |
| Payout Ratio | 2.69 | 1.12 | 34.43 | 1.33 | 0.75 | 0.71 | |
| Capex To Operating Cash Flow | (0.52) | (0.83) | (0.54) | (0.37) | (0.26) | (0.38) | |
| Pfcf Ratio | 254.88 | 59.86 | 44.18 | 29.23 | 32.04 | 33.64 | |
| Days Payables Outstanding | 1.0K | 1.1K | 555.79 | 560.86 | 144.23 | 137.01 | |
| Income Quality | 1.92 | 1.23 | (22.5) | 3.92 | 1.5 | 1.57 | |
| Roe | 0.2 | 0.17 | 0.1 | 0.002852 | 0.0888 | 0.14 | |
| Ev To Operating Cash Flow | 48.03 | 29.97 | 31.98 | 23.92 | 22.54 | 28.84 | |
| Pe Ratio | 97.18 | 41.07 | 1.5K | 64.34 | 35.33 | 58.74 | |
| Return On Tangible Assets | 0.0799 | 0.0462 | 0.0942 | 0.002606 | 0.088 | 0.14 | |
| Ev To Free Cash Flow | 280.14 | 65.58 | 50.68 | 32.42 | 35.51 | 37.28 | |
| Earnings Yield | 0.0103 | 0.0243 | 6.74E-4 | 0.0155 | 0.0283 | 0.0557 |
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving against AstraZeneca Stock
| 0.81 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.72 | CRBU | Caribou Biosciences Financial Report 14th of May 2024 | PairCorr |
| 0.6 | MOLN | Molecular Partners Financial Report 10th of May 2024 | PairCorr |
| 0.57 | NAUT | Nautilus Biotechnology Financial Report 7th of May 2024 | PairCorr |
| 0.54 | IPSC | Century Therapeutics Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.207 | Dividend Share 2.9 | Earnings Share 2.02 | Revenue Per Share 2.5512 | Quarterly Revenue Growth 0.165 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.